- 期刊
Pembrolizumab治療子宮頸癌的檢視
The Role of Pembrolizumab in Management of Cervical Cancer
摘要
免疫治療對子宮頸癌的生成、惡化和存活有相當的重要性，並對以前因化療等所產生的免疫抑制，功能恢復正常。Pembrolizumab計劃細胞死亡接受器1（PD-1）的免疫檢查點阻斷劑，乃為人類單株免疫球蛋白G4（IgG4）抗體，它可阻止與T細胞中PD-1與其計劃細胞死亡接受器配體（PD-L1）的結合，使T細胞恢復活性，抑制腫瘤細胞。最近研究證明，以pembrolizumab來治療晚期、復發和持續性的子宮頸癌會有效果。
並列摘要
The immune system plays an active role in the pathogenesis of cervical cancer, as well as the mechanisms of disease progression and overall survival. Immunotherapy in gynecological cancer could help to revert immunosuppression due to prior treatment. Pembrolizumab, a checkpoint inhibitor of programmed-cell-death-receptor 1(PD-1), is a fully humanized monoclonal immunoglobulin G4 (IgG4) antibody and it binds to PD-1 on T-cells therby inhibiting interactions with its ligand, proprammed death ligand-1(PD-L1), which is primarily expressed on tumor cells. As a result, T-cells are activated and can attack cancer cells. Pembrolizumab is currently also being studies for use in cervical cancer with recent studies indicating promising results in advanced, recurrent, or persistent cervical cancer.
延伸閱讀
- 李耀泰、陳福民、郭宗正（2017）。以Bevacizumab治療子宮內膜癌的檢視。婦癌醫學期刊，(46)，19-22。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-201710-201710250011-201710250011-19-22
- 李耀泰、陳福民、郭宗正（2011）。Topotecan治療子宮頸癌的檢視。中華民國婦癌醫學雜誌，(2011年1)，15-24。https://doi.org/10.7010/JGO.201104.0015
- 鄭乃銘、王鵬惠、屠乃方（2021）。子宮頸癌接受合併化學放射線治療產生急性生殖道出血的成功處置經驗：個案報告及文獻回顧止血治療策略。婦癌醫學期刊，(54)，12-15。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-202110-202201280017-202201280017-12-15
- 李耀泰、陳福民、林大欽、郭宗正（2007）。以carboplatin爲主之子宮頸癌化學治療。中華民國婦癌醫學雜誌，(2007年2)，54-60。https://doi.org/10.7010/JGO.200710.0054
- 李耀泰、陳福民、郭宗正（2021）。The role of pembrolizumab and ipilimumab for the treatment of ovarian cancer。婦癌醫學期刊，(53)，1-5。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-202104-202105050007-202105050007-1-5